8-K
filed March 12, 2026, 7:59 PM ET
ticker CCEL
CIK 0000862692
regulatory
confidence high
sentiment negative
materiality 0.80
Cryo-Cell receives NYSE American delisting notice over stockholders' deficit and net losses
CRYO CELL INTERNATIONAL INC
- NYSE American cited stockholders' deficit as of Nov 30, 2025 and net losses in two of three fiscal years ended Nov 30, 2025.
- Company must submit compliance plan by April 8, 2026; if accepted, extension up to 18 months possible.
- Trading of CCEL common stock continues on NYSE American while company pursues compliance plan.
- No assurance that plan will be accepted or that compliance can be regained; delisting possible if not.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-26-104392
- form_type
- 8-K
- ticker
- CCEL
- cik
- 0000862692
- company_name
- CRYO CELL INTERNATIONAL INC
- filed_at
- 2026-03-12T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:37.844572+00:00
- generated_at
- 2026-05-15T14:33:39.878653+00:00
- sec_items
- ["3.01", "7.01", "9.01"]
- event_type
- regulatory
- sentiment
- negative
- materiality_score
- 0.8
- calibrated_materiality_score
- 0.8
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-26-104392
- json_url
- https://secwatch.observer/filing/0001193125-26-104392.json
- markdown_url
- https://secwatch.observer/filing/0001193125-26-104392.md
- text_url
- https://secwatch.observer/filing/0001193125-26-104392.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/0001193125-26-104392-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/ccel-20260309.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
ATNM
Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26
Actinium Pharmaceuticals, Inc.
May 29, 2026, 5:10 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance. In accordance with NYSE American procedures, the Company intends to submit a plan of
Comparable filing
May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately
Filing page
SEC filing
CDT
CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan
CDT Equity Inc.
May 28, 2026, 4:30 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance. In accordance with NYSE American procedures, the Company intends to submit a plan of
Comparable filing
May 21, 2026, CDT Equity Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Listing
Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with
Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”) because the Company did not file its Quarterly Report
on Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”) in a timely manner, as required for continued
listing on The Nasdaq Capital Market. The Notice has no immediate effect on the listing or trading of the Company’s
Filing page
SEC filing
CHAR
Charlton Aria receives Nasdaq delinquency notice for untimely Q1 10-Q filing
Charlton Aria Acquisition Corp
May 27, 2026, 4:41 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance. In accordance with NYSE American procedures, the Company intends to submit a plan of
Comparable filing
May 22, 2026, Charlton
Aria Acquisition Corporation (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications
Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that
Filing page
SEC filing
VSTD
Vestand receives Nasdaq delisting notice for late quarterly and annual filings
Vestand Inc.
May 26, 2026, 5:18 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance. In accordance with NYSE American procedures, the Company intends to submit a plan of
Comparable filing
May 19, 2026, the Company received a Staff Delisting Determination letter (the “Staff Determination”) from Nasdaq notifying
it that Nasdaq has initiated a process which could result in the delisting of the Company’s secu
Filing page
SEC filing
NVVE
Nuvve receives Nasdaq delisting notice for late Q1 10-Q filing; already under $1.00 bid price review
Nuvve Holding Corp.
May 22, 2026, 6:35 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance. In accordance with NYSE American procedures, the Company intends to submit a plan of
Comparable filing
May 22, 2026, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company
Filing page
SEC filing
AGAE
AGAE receives Nasdaq delisting notice over bid price <$1.00 and late 10-K; will appeal
Allied Gaming & Entertainment Inc.
May 11, 2026, 5:09 PM ET
regulatory
Items 3.01, 5.03, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance. In accordance with NYSE American procedures, the Company intends to submit a plan of
Comparable filing
termination
before an independent Hearings Panel (the “Panel”) by May 13, 2026. On November 4, 2025, Staff notified the Company
that the bid price of the Common Stock had closed at less than $1.00 per share over 30 consecutive business days, and, as a result, did
not comply with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Staff Determination was issued pursuant
to Nasdaq Listing Rule 5810(c)(3)(A) on the grounds that the Company has not regained compliance with the Minimum Bid Price Rule during
a 180-day compliance period and is not eligible for a second 180-day complian
Filing page
SEC filing
SBEV
Splash Beverage receives NYSE delisting notice; shareholders' equity negative $15.3M
SPLASH BEVERAGE GROUP, INC.
May 5, 2026, 7:59 PM ET
regulatory
Items 1.01, 1.02, 3.01, 3.02, 5.03, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance. In accordance with NYSE American procedures, the Company intends to submit a plan of
Comparable filing
April 29, 2026, the Company received notice from NYSE Regulation (the “NYSE”)
that the Company is not in compliance with the shareholders’ equity requirement of $6 million as of December 31, 2025 as outlined
in Section 1
Filing page
SEC filing
VSTD
Vestand receives Nasdaq delisting notice for late 10-K filing; may submit compliance plan by May 18, 2026
Vestand Inc.
April 29, 2026, 7:59 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance. In accordance with NYSE American procedures, the Company intends to submit a plan of
Comparable filing
April 23, 2026, Vestand Inc. (the “Company”) received a staff deficiency notice (the “Notice”) from The Nasdaq
Stock Market (“Nasdaq”) indicating that, because Nasdaq has not yet received the Company’s Form 10-K for the
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.